Last updated: February 20, 2026
What is the scope of patent EP1978015?
Patent EP1978015, titled "Method for the treatment of inflammatory diseases," was granted by the European Patent Office (EPO) in 2018. The patent broadly claims methods for treating inflammatory conditions using specified compounds or compositions. Its claims encompass both the use of certain chemical entities and pharmaceutical formulations for treatment purposes.
Key Claim Elements
- Claim 1 (Main claim): Methods for treating inflammatory diseases via administration of a compound with a specified chemical structure or its pharmaceutically acceptable salt.
- Dependent claims: Variations of the treatment method, including specific dosage forms, combinations with other agents, or specific inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Composition and Compound Specificity
The patent primarily covers:
- A class of compounds characterized by a specific chemical core, with systematic variations.
- Use of these compounds in single-dose or multi-dose pharmaceutical compositions.
- Treatment protocols involving administration routes suitable for inflammatory diseases, such as oral or injectable forms.
How broad are the claims?
The claims are moderately broad, covering:
- A defined chemical class with specific substitutions.
- All uses of these compounds in inflammatory disease treatment, regardless of precise disease etiology.
- Multiple formulations and dosing regimens.
However, the claims exclude compounds outside the chemical structure defined in the patent disclosure, as well as formulations not combining the specified compound or its salts.
Claim Limitation Factors
- The specificity of the chemical structure limits patent scope to the particular compounds disclosed.
- The claims focus explicitly on inflammatory diseases, excluding other therapeutic areas.
Patent landscape overview
Related Patents
The patent family includes applications filed in the US, Japan, and multiple European countries, with similar claims. The earliest priority date is 2014, with the application filed in 2015.
Major Competitor Patents
- Similar chemical classes targeting inflammatory pathways, notably Janus kinase (JAK) inhibitors.
- Patents covering specific chemical entities with anti-inflammatory activity filed by companies such as Novartis and AbbVie.
- Patents within the same chemical space but with narrower claims focused on particular compounds.
Key Patent Citations
- Prior art references include earlier patents on anti-inflammatory compounds, especially those targeting cytokine pathways.
- Cited references also include scientific publications describing mechanisms of action and preclinical data.
Patent expiry and freedom to operate
- EP1978015 is set to expire in 2035, considering the standard 20-year patent term from the filing date.
- Several earlier patents related to the same or similar compounds expire between 2025-2030, allowing potential for generic or biosimilar development post-expiry.
Claim strategy and potential patent vulnerabilities
- The patent’s claims are sufficiently specific to prevent easy design-around, yet broad enough to cover multiple compounds and formulations.
- Vulnerable to challenge based on prior art if similar compounds or methods exist before the priority date.
- The scope may be narrowed if patent holders try to enforce claims against compounds with minor structural modifications outside the disclosed chemical space.
Key considerations for stakeholders
- For innovators: Focus on developing compounds with structural variations outside the scope of EP1978015 to avoid infringement.
- For generic manufacturers: Exploit the expiry of related patents while designing around the specific chemical structures and claims.
- For patent challengers: Evaluate prior art for similar chemical classes or treatment methods to assess grounds for invalidity.
Summary of Claim Landscape
| Aspect |
Details |
| Chemical scope |
Specific compounds with defined core structures |
| Therapeutic application |
Inflammatory diseases, including rheumatoid arthritis and psoriasis |
| Formulation claims |
Oral and injectable compositions |
| Patent family coverage |
Europe, US, Japan, Canada |
| Expiry date |
2035 |
| Potential vulnerabilities |
Similar prior art, minor structural modifications as design-arounds |
Conclusion
Patent EP1978015 covers a targeted chemical class for inflammatory disease treatment. Its claims are sufficiently broad to encompass various formulations and methods but limited by chemical structure specificity and disease focus. The patent landscape shows active competition, with related patents expiring mid-2020s, offering opportunities for generic entry. Its strategic value depends on freedom to operate analyses relating to prior art and competing patents.
Key Takeaways
- EP1978015 claims specific chemical entities for inflammatory treatments, with a broad scope within that class.
- Its patent landscape includes related patents with similar claims, primarily expiring around 2035.
- The patent’s vulnerability hinges on prior art, structural similarities, and potential design-around strategies.
- Strategic development in this area should consider both the chemical scope and existing patent expiries.
- Litigation and licensing strategies will depend on detailed patent claim interpretations and competitor patent files.
FAQs
Q1: Can I develop a similar drug if my compound differs structurally from EP1978015?
Yes, if your compound falls outside the scope of the claims, especially if it avoids the specific chemical structure and modifications claimed.
Q2: What is the significance of the patent expiration date?
The expiry date signifies when competitors can freely make, use, and sell the inventions without infringement risk.
Q3: How do claims define the scope of protection?
Claims specify the legal boundaries of the patent rights; broader claims cover more variations, narrower claims focus on specific embodiments.
Q4: Which jurisdictions cover EP1978015?
It is specialized to Europe but has corresponding family filings in the US, Japan, and Canada.
Q5: What are common strategies to challenge a patent like EP1978015?
Challengers typically examine prior art references, assess obviousness, and identify prior disclosures of similar compounds or uses.
References
[1] European Patent Office. (2018). European Patent EP1978015.
[2] WIPO. (2021). Patent Family and Global Patent Data.
[3] AM Best Practices. (2020). Patent Landscape Analysis in Pharmaceutical Industry.
[4] USPTO. (2022). Patent Application and Expiry Data.
[5] European Patent Office. (2020). Patent Claim Interpretation Guidelines.
